BRISTOL MYERS SQUIBB
- Country
- 🇺🇸United States
- Ownership
- -
- Established
- 1989-01-01
- Employees
- 30K
- Market Cap
- $97.5B
- Website
- https://www.bms.com/
A Study to Evaluate Safety and Efficacy of KarXT + KarX-EC as a Treatment for Psychosis Associated With Alzheimer's Disease (ADEPT-5)
- Conditions
- Alzheimer DiseasePsychosis
- Interventions
- First Posted Date
- 2025-04-27
- Last Posted Date
- 2025-04-27
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 1046
- Registration Number
- NCT06947941
A Study to Evaluate Two Dosing Regimens of Subcutaneous Nivolumab in Combination With Intravenous Ipilimumab and Chemotherapy in Participants With Previously Untreated Metastatic or Recurrent Non-Small Cell Lung Cancer (NSCLC)
- Conditions
- Non-Small Cell Lung Cancer
- Interventions
- First Posted Date
- 2025-04-27
- Last Posted Date
- 2025-05-11
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 76
- Registration Number
- NCT06946797
- Locations
- 🇵🇱
Local Institution - 0079, Łódź, Łódzkie, Poland
🇧🇷Local Institution - 0041, Brasilia, Distrito Federal, Brazil
🇺🇸Local Institution - 0032, Anchorage, Alaska, United States
A Study to Evaluate the Long-term Efficacy and Safety of KarXT + KarX-EC for Agitation in Alzheimer's Disease (ADAGIO-3)
- First Posted Date
- 2025-04-22
- Last Posted Date
- 2025-05-28
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 600
- Registration Number
- NCT06937229
- Locations
- 🇺🇸
Local Institution - 2609, Chandler, Arizona, United States
🇺🇸Local Institution - 1619, Scottsdale, Arizona, United States
🇺🇸Local Institution - 2620, Canoga Park, California, United States
Phase 1 Study of MRTX1719 in Solid Tumors With MTAP Deletion
- Conditions
- MesotheliomaNon Small Cell Lung CancerMalignant Peripheral Nerve Sheath TumorsSolid TumorPancreatic AdenocarcinomaAdvanced Solid Tumor
- Interventions
- First Posted Date
- 2025-04-22
- Last Posted Date
- 2025-04-22
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 320
- Registration Number
- NCT06937970
- Locations
- 🇺🇸
Mayo Clinic, Rochester, Minnesota, United States
🇺🇸Rocky Mountain Cancer Centers, LLP - Oncology, Lone Tree, Colorado, United States
🇺🇸Sarah Cannon Research Institute (SCRI) - HealthONE Location, Denver, Colorado, United States
A Study to Assess the Long-term Safety of KarXT for the Treatment of Manic Episodes in Bipolar-I Disorder (BALSAM-3)
- First Posted Date
- 2025-04-16
- Last Posted Date
- 2025-05-28
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 300
- Registration Number
- NCT06929273
- Locations
- 🇺🇸
Local Institution - 0123, Torrance, California, United States
🇺🇸Local Institution - 0026, Hialeah Gardens, Florida, United States
🇺🇸Local Institution - 0059, Hollywood, Florida, United States
A Study of Izalontamab Brengitecan Versus Chemotherapy in Participants With Previously Untreated, Locally Advanced, Recurrent Inoperable, or Metastatic Triple-negative Breast Cancer Ineligible for Anti-PD(L)1 Drugs (IZABRIGHT-Breast01)
- Conditions
- Breast Neoplasms
- Interventions
- First Posted Date
- 2025-04-15
- Last Posted Date
- 2025-05-18
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 560
- Registration Number
- NCT06926868
- Locations
- 🇺🇸
Local Institution - 0303, Hot Springs, Arkansas, United States
🇺🇸Local Institution - 0307, Cerritos, California, United States
🇺🇸Local Institution - 0308, Cerritos, California, United States
A Study to Investigate the Safety, Tolerability, and Drug Levels of BMS-986419 (Part 1) and the Effects Multiple Doses of BMS-986419 on Cardiac Repolarization (Part 2) in Healthy Participants
- Conditions
- Healthy Volunteers
- Interventions
- Drug: BMS-986419 Matching PlaceboDrug: Moxifloxacin Matching Placebo
- First Posted Date
- 2025-03-25
- Last Posted Date
- 2025-04-01
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 74
- Registration Number
- NCT06846866
- Locations
- 🇺🇸
Celerion, Tempe, Arizona, United States
A Study to Evaluate the Efficacy and Safety of KarXT in Acutely Psychotic Japanese Adult Participants With Schizophrenia
- First Posted Date
- 2025-03-19
- Last Posted Date
- 2025-05-28
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 250
- Registration Number
- NCT06882785
- Locations
- 🇯🇵
Local Institution - 0034, Konan, Aichi, Japan
🇯🇵Local Institution - 0001, Toyoake, Aichi, Japan
🇯🇵Local Institution - 0003, Toyoake, Aichi, Japan
A Study to Continue the Administration of Deucravacitinib in Participants With Systemic Lupus Erythematosus (SLE) or Discoid and/or Subacute Cutaneous Lupus Erythematosus (DLE/SCLE) Who Have Completed Study IM011074 or Study IM011132
- Conditions
- Systemic Lupus Erythematosus (SLE)Discoid and/or Subacute Cutaneous Lupus Erythematosus (DLE/SCLE)
- Interventions
- First Posted Date
- 2025-03-14
- Last Posted Date
- 2025-03-14
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 35
- Registration Number
- NCT06875960
- Locations
- 🇺🇸
Local Institution - 0001, Farmington, Connecticut, United States
🇺🇸Local Institution - 0002, New York, New York, United States
🇺🇸Local Institution - 0003, Jackson, Tennessee, United States
A Single-dose Study to Evaluate the Safety, Tolerability, Drug Levels, and Relative Biological Availability of Alternate Formulations of BMS-986460 in Healthy Adult Male Participants
- First Posted Date
- 2025-03-14
- Last Posted Date
- 2025-05-15
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 56
- Registration Number
- NCT06877702
- Locations
- 🇺🇸
ICON Lenexa, Lenexa, Kansas, United States
🇺🇸Local Institution - 0002, Lenexa, Kansas, United States